Enlivex Ltd. (TLV:ENLV)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 630.17M +659.0% |
| Revenue (ttm) | n/a |
| Net Income | 3.94B |
| EPS | 81.23 |
| Shares Out | n/a |
| PE Ratio | 0.16 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 81,638 |
| Open | 265.00 |
| Previous Close | n/a |
| Day's Range | 260.00 - 292.00 |
| 52-Week Range | 213.20 - 682.90 |
| Beta | 1.68 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jun 15, 2026 |
About Enlivex
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was forme... [Read more]
News
ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026
As a Gold Sponsor of the Paris event, Enlivex will host a curated dinner today for leading institutional asset managers, allocators, and digital asset investors Nes-Ziona, Israel, June 02, 2026 (GLOBE...
Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026
The data were selected for an oral podium presentation at EULAR and will be presented by Prof. Philip Conaghan, a globally recognized key opinion leader in osteoarthritis Nes-Ziona, Israel, June 01, 2...
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board
As of May 27, 2026, Enlivex held 79,568,550,005 RAIN tokens with a total value of approximately $1.16 billion. Separately, the Rain Foundation recently announced the appointment of five industry leade...
Enlivex comments on $100M commitment to Rain’s prediction market
Enlivex commented on the Rain Foundation’s announcement of a $100M liquidity commitment to Rain’s prediction markets protocol, which currently positions Rain as the third-largest prediction market pro...
Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity
Rain, with an additional $100 Million Liquidity Commitment, Currently Anchors Top Three Positioning Among Global Prediction Market Leaders, Following Polymarket, with Approximately $450 million, and K...
Enlivex Therapeutics doses first patient in Allocetra trial
Enlivex announced the dosing of the first patient at a United States clinical site in the Phase 2b clinical trial of Allocetra for the treatment of patients with moderate-to-severe age-related…
Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Enrollment milestone follows FDA IND clearance received in March 2026 and Danish Medicines Agency (DKMA) approval received in April 2026 Nes-Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd...
Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification
Nes-Ziona, Israel, May 15, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced that ...
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange
The listing on one of the world's largest global cryptocurrency exchanges expands market access and secondary liquidity for Enlivex's primary digital treasury asset
Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million
New acquisitions from Rain Foundation underlines Enlivex's disciplined prediction markets treasury strategy Nes-Ziona, Israel, April 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” ...
Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress
Nes-Ziona, Israel, April 23, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced tha...
Enlivex Therapeutics files to sell 23.33M ordinary shares for holders
16:19 EDT Enlivex Therapeutics (ENLV) files to sell 23.33M ordinary shares for holders
Enlivex receives CTA approval by DKMA for Phase 2b trial of Allocetra
Enlivex announced that it has received Clinical Trial Application, CTA, approval by the Danish Medicines Agency, DKMA, for the Phase 2b trial of Allocetra, the Company’s clinical-stage immunotherapy, ...
Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Nes-Ziona, Israel, April 21, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) (“Enlivex” or the “Company”), a quality longevity company, today announced that it has received Clinical Trial Applica...
Enlivex Registration statement: Registration filing
Enlivex filed a registration statement on April 21, 2026, providing details about a securities offering with the SEC.
Ondo Global Markets Tokenizes Enlivex's Ordinary Shares
Nes-Ziona, Israel, April 08, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced tha...
Enlivex Therapeutics price target raised to $20 from $13 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Enlivex Therapeutics (ENLV) to $20 from $13 and keeps a Buy rating on the shares. The company’s debt financing…
Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt
According to the Rain Foundation, anyone using OpenClaw or other AI agents can generate a live prediction market via a single prompt to the agent, without manual coding or centralized gatekeepers ...
Enlivex Earnings Call Transcript: Q4 2025
2025 saw record net income and EPS, driven by treasury gains from prediction markets, especially RAIN tokens. Clinical progress continued with FDA clearance for a Phase IIb osteoarthritis trial, while new financing and share repurchase initiatives support future growth.
Enlivex Annual report: Q4 2025
Enlivex has published its Q4 2025 annual report on March 25, 2026.
Enlivex Quarterly report: Q4 2025
Enlivex has published its Q4 2025 quarterly earnings report on March 25, 2026.
Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48
Earnings Driven by Treasury and Treasury-Related Asset Appreciation Nes-Ziona, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV; “Enlivex” or “the Company”) today reported financi...
Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program
$21 Million debt financing, convertible to ENLV ordinary shares at fixed $2.69175 per share, a 264% premium to the Nasdaq closing price on March 20, 2026, with a single institutional investor The Comp...
Enlivex Slides: Investor presentation
Enlivex has posted slides in relation to its latest quarterly earnings report, which was published on March 24, 2026.
Enlivex Therapeutics announces FDA clearance of Allocetra new drug application
Enlivex announced that the FDA has cleared its investigational new drug application for Allocetra, the company’s clinical-stage immunotherapy, for the treatment of patients with moderate-to-severe age...